Mumbai, March 6 -- The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This

investment aligns with the company's strategic growth plans and long-term business objectives.

Published by HT Digital Content...